Skip to Main Content
Alison Bateman-House

Alison Bateman-House, MPH, PhD

Assistant Professor, Department of Population Health

Keywords
Clinical trials, Compassionate use, Access to investigational medical products
Summary

I am an ethicist, a public health professional, and a medical historian. My research is primarily focused on ethics and policy issues concerning access to investigational medical products, both inside and outside of clinical trials. One particular area of interest is in the equity of access: who gets access to what, how?
In recent years, my colleagues and I have become interested in several areas of active inquiry: 1) can useful efficacy data be obtained from non-trial uses of unapproved medical products; 2) how to most ethically and pragmatically advance the new field of individualized therapeutics; 3) the ethics of pediatric gene therapy trials; and 4) what amount of and quality of data is needed to make clinical & regulatory decisions.
I am also interested in and conducted research on the history, ethics, & public policy of mandatory helmet laws.

Phone

646-359-9318

Fax

646-501-2830

Academic office

227 East 30th Street

7th Floor, #723

New York, NY 10016

Is this your profile?
Edit profile

These focus areas and their associated publications are derived from medical subject headings from PubMed.
represents one publication
Loading...
*Due to PubMed processing times, the most recent publications may not be reflected in the timeline.

Positions

Assistant Professor, Department of Population Health at NYU Grossman School of Medicine

Graduate Education

PhD from Columbia University

MPH from Columbia University

Postdoctoral Training

NYU Grossman School of Medicine, Division of Medical Ethics

Project pErception of coVID tEsting aNd vaCcinE (EVIDENCE)

See All Studies (1)

Right-to-Try Laws: Hope, Hype, and Unintended Consequences

Bateman-House, Alison; Kimberly, Laura; Redman, Barbara; Dubler, Nancy; Caplan, Arthur

Annals of internal medicine. 2015 Nov 17; 163(10):796-7

Should patients in need be given access to experimental drugs?

Caplan, Arthur L; Bateman-House, Alison

Expert opinion on pharmacotherapy. 2015 Jun; 16(9):1275-9

Somatic Gene Therapy Research in Pediatric Populations: Ethical Issues and Guidance for Operationalizing Early Phase Trials

Bateman-House, Alison; Shah, Lesha D; Escandon, Rafael; McFadyen, Andrew; Hunt, Cara

Pharmaceutical medicine. 2022 Dec 17;

Perspectives of Academic Oncologists About Offering Expanded Access to Investigational Drugs

Gould, Patrick; Salam, Tasnim; Kimberly, Laura; Bateman-House, Alison; Fernandez Lynch, Holly

JAMA network open. 2022 Nov 01; 5(11):e2239766

Individualized Therapeutics Development for Rare Diseases: The Current Ethical Landscape and Policy Responses

Bateman-House, Alison; Kearns, Lisa

Nucleic acid therapeutics. 2022 Apr; 32(2):111-117

Fetal Therapies and Clinical Research: Beyond Risk and Benefit

Shah, Lesha D.; Lantos, John; Hunt, Cara; McFadyen, Andrew; Escandon, Rafael; Bateman-House, Alison

American journal of bioethics : AJOB. 2022 Jan 01; 22(<prism:issueIdentifier>3):1-3

Helpful Lessons and Cautionary Tales: How Should COVID-19 Drug Development and Access Inform Approaches to Non-Pandemic Diseases?

Lynch, Holly Fernandez; Caplan, Arthur; Furlong, Patricia; Bateman-House, Alison

American journal of bioethics : AJOB. 2021 Oct 19; 1-16

Gene therapy companies have an ethical obligation to develop expanded access policies

Kearns, Lisa; Chapman, Carolyn Riley; Moch, Kenneth I; Caplan, Arthur L; Watson, Tom; McFadyen, Andrew; Furlong, Pat; Bateman-House, Alison

Molecular therapy. 2021 Apr 07; 29(4):1367-1369

See All Publications (44)